Prescription
Access to medicinal cannabis prescriptions
In Australia, access to medicinal cannabis prescriptions is tightly regulated by the Therapeutic Goods Administration (TGA) and requires a series of steps for pharmacies and practitioners to follow.
For practitioners:
Obtain appropriate qualifications and registration to prescribe Schedule 8 medicines. Medicinal cannabis products are classified as Schedule 8 (controlled drugs) under the Australian Poisons Standard.
Ensure patients meet the eligibility criteria set by the TGA. Medicinal cannabis is only approved for use in certain medical conditions where standard treatments have failed.
Assess patient suitability for medicinal cannabis treatment and determine the appropriate dosage and product type.
Apply for approval from the TGA to prescribe the specific medicinal cannabis product for the patient.
Issue the prescription for the approved product and dose, ensuring that the prescription complies with relevant state or territory regulations.
Monitor the patient's progress and review the ongoing suitability of medicinal cannabis treatment.
For pharmacies:
Obtain the necessary licenses and permits to dispense medicinal cannabis products.
Ensure that the practitioner has obtained TGA approval to prescribe the specific medicinal cannabis product.
Verify the prescription and check that it complies with relevant state or territory regulations.
Source the approved medicinal cannabis product from a licensed supplier.
Dispense the product to the patient and provide appropriate counseling on use, side effects, and storage.
Keep detailed records of all medicinal cannabis transactions.
It's important to note that medicinal cannabis is a highly regulated substance in Australia, and both practitioners and pharmacies must adhere to strict guidelines and regulations when prescribing and dispensing these products.
The rise in demand for medical marijuana has to do with the discovery and research of the endocannabinoid systems which is responsible for regulating health and creating homeostatic.
Anti-Oxidant Properties
It is well documented that fruits bear ample supply of anti-oxidants in the form of Vitamin C. New research centered on the effects of Marijuana CBD Oil as anti-oxidant molecules reveal that the CBD is a powerful anti-oxidant. Additionally, various publish research article indicate that in most cases, CBD molecules are non-toxic for human consumption.
Anti-oxidants molecules are molecules that inhibit the oxidation process. Oxidation is a reaction which yields free-radicals that cause a chain reaction with stored food particles, leading to the deterioration of the food particles as well as body cells. Therefore, CBD can be used to maintain proper health of cells, promoting wholesome body health.
Cannabis is now widely recognised as a treatment for numerous conditions and according to the medical cannabis clinic, the 10 most common conditions Medical Cannabis Is prescribed for are:
1. Multiple Sclerosis
2. Spinal Cord Injury
3. Spinal Cord Disease
4. Cancer
5. HIV/AIDS
6. Arthritis
7. Epilepsy
8. Inflammatory Bowel Disease
9. End of Life Care
10. Insomnia
Welcome to Cannabis Prescription in Australia and New Zealand by Medicinal Organic Cannabis Australia (MOCA). As the Australian and New Zealand markets have opened up over the last few years, so has the demand for medicinal cannabis medication. MOCA is a fully licensed medical cannabis company based with its headquarters in Sydney Australia and offices in New Zealand.
The company imports a range of cannabidiol (CBD) products and THC rich medications. We wholesale these products to approved pharmacy and health care professionals.
MOCA has developed a new product that aims to revolutionise the wholesale cannabis industry in Australia. Our business focuses on increasing patient access by significantly reducing costs of medication and providing organic options.
MOCA has 21 products currently approved by the Australian Federal Government and we hold import permits for all the products from the Office of Drug Control.
The growth in medical cannabis demand has seen exponential rise in demand for patient access to medication, in Australia and internationally. In Australia, patient numbers for approved medications has risen slowly since legalisation in 2016 and as at early 2019, approximately 3500 patients have been approved under the special access scheme.
This of course has created immense interest in medical marijuana as a form of treatment and as investment opportunities as more and more people are seeking to invest in marijuana. The international market is expected to reach over US$500 billion in the coming decade and is still in its infancy.